13/09/2017 18:05:40

Plaintiffs Dismiss Class Action Appeal Against Accelerate Diagnostics

Related content
03 Aug - 
Accelerate Diagnostics Reports Q2 2017 Financial Result..
31 Jul - 
Accelerate Diagnostics Welcomes Dr. Romney Humphries as..
18 Jul - 
Accelerate Diagnostics Schedules Call to Review Second ..

TUCSON, Ariz., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today that the United States Court of Appeals for the Ninth Circuit signed an order dismissing the plaintiffs’ Appeal of their class action lawsuit filed against Accelerate and certain of its executives. Shortly before the Appeal was scheduled to be argued, the plaintiffs/appellants voluntarily requested that their case be dismissed.

“This is a case that should have never been brought,” said Steven Schatz of Wilson Sonsini who represented Accelerate and its executives.  “Accelerate and the individual defendants acted entirely properly.  I am pleased that they have been vindicated.  They should not have had to bear the distraction and cost of this suit.” The lawsuit was filed in March of 2015 against the company, its President and CEO, Lawrence Mehren, and CFO, Steve Reichling, and alleged that the defendants violated Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 by making false or misleading statements about the Accelerate Pheno™ system, formerly called the BACcel System. The defendants denied all such allegations.

In January of last year, the U.S. District Court in Arizona granted the defendants’ motion to dismiss the case with prejudice.  The Appeal was subsequently filed by the plaintiffs challenging the decision of the district court. A year and a half later, after fully briefing the case and on the cusp of oral arguments, the plaintiffs abandoned their Appeal.  The plaintiffs – without seeking a settlement with the defendants -requested that the Ninth Circuit dismiss their case.  The Appeal was docketed as Chang v. Accelerate Diagnostics, Inc., et al., No. 2:15-CV-00504-SPL (9th Cir. filed Feb. 26, 2016).

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. ("Accelerate") (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and healthcare-associated infections.  The company recently obtained FDA marketing authorization for antimicrobial susceptibility testing direct from positive blood culture samples using its Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit.  The system and kit leverage proprietary molecular identification methods and morphokinetic cellular analysis (MCA) to provide minimum inhibitory concentrations for a range of applicable antibiotics.  The fully-automated system is designed to eliminate the lengthy culture and sample preparation steps required prior to antimicrobial susceptibility testing.  Recent market studies suggest the solution offers results 1-2 days faster than conventional methods, enabling clinicians to optimize antibiotic selection, dosage, and infusion strategy specific to the individual patient and their infection.

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.

For more information about the company, its products or technology, visit axdx.com.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, about our projections as to market need, acceptance and integration of our products.  Actual results or developments may differ materially from those projected or implied in these forward-looking statements.  Information about the risks and uncertainties faced by Accelerate is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 28, 2017, and in any other reports that we file with the Securities and Exchange Commission from time to time.  The company's forward-looking statements could be affected by general industry and market conditions.  Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.

Investor and Media inquiries:

Andrew Chasteen

Accelerate Diagnostics

+1 520 404-0809


Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Alliance Trust PLC : Net Asset Value(s)

25/09/2017 13:10:52
ALLIANCE TRUST PLC                                    At the close of business on Friday 22 September 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 748.1p -       including income, 756.0p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding in..

Form 8.5 (EPT/RI) - Booker Group plc

25/09/2017 08:07:28
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant se..

Alliance Trust PLC : Transaction in Own Shares

25/09/2017 07:39:49
25 September 2017  Alliance Trust PLC TRANSACTION IN OWN SHARES  The Board of Alliance Trust PLC ("the Company") announces that on 22 September 2017 the Company purchased for cancellation 54,330 ordinary shares of 2.5p each at a price of 704.6964p per share.  Therefore, the total number of voting rights in the Company is now 349,635,321.    The above figure (349,635,321) may be used by sh..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
Gigya, the Market Leader in Customer Identity and Access Management, to be Acquired by SAP
iLOOKABOUT Launches New Mobile Appraiser Product at IAAO Conference
Aerojet Rocketdyne Supports ULA Launch of Classified Satellite for the U.S. Government
OCEANTEAM ASA - Dutch Jos van Dijk appointed Group Chief Financial Officer (CFO)
Thinfilm Launches NFC Scanner App for iPhones as Apple Extends NFC Functionality Beyond Payments with Release of iOS 11

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
25 September 2017 14:30:50
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170921.1 - EUROWEB3 - 2017-09-25 15:30:50 - 2017-09-25 14:30:50 - 1000 - Website: OKAY